Drugs Monitor, Page 20

(04 Nov 2020) Azithromycin, Nitazoxanide, Ivermectin and HCQ- AZT in combination with drugs proven beneficial

November 9, 2020

Early COVID-19 Therapy with Azithromycin Plus Nitazoxanide, Ivermectin or Hydroxychloroquine in Outpatient Settings Significantly Reduced Symptoms Compared to Known Outcomes in Untreated Patients https://www.medrxiv.org/content/10.1101/2020.10.31.20223883v1.full.pdf The objective of the present study (NCT04446429) was to elucidate whether the conduction of a full… Continue reading "(04 Nov 2020) Azithromycin, Nitazoxanide, Ivermectin and HCQ- AZT in combination with drugs proven beneficial"

(03 Nov 2020) Remdesivir- significantly higher rates of clinical improvement

November 5, 2020

Remdesivir-based therapy improved recovery of patients with COVID-19 in the SARSTer multicentre, real-world study https://doi.org/10.1101/2020.10.30.20215301 The purpose of this study was to evaluate the effectiveness and safety of RDV in patients with COVID-19 in real world settings. Patients were selected… Continue reading "(03 Nov 2020) Remdesivir- significantly higher rates of clinical improvement"

(03 Nov 2020) Ivermectin- associated 73% reduction of COVID-19 infection among healthcare workers

November 5, 2020

Role of ivermectin in the prevention of COVID-19 infection among healthcare workers in India: A matched case-control study https://www.medrxiv.org/content/10.1101/2020.10.29.20222661v1 A hospital-based matched case-control study was conducted among healthcare workers of AIIMS Bhubaneswar, India, from September to October 2020. Ivermectin prophylaxis… Continue reading "(03 Nov 2020) Ivermectin- associated 73% reduction of COVID-19 infection among healthcare workers"

(03 Nov 2020) Tocilizumab- significantly reduced the need for invasive ventilation and mortality

November 5, 2020

Tocilizumab Use in COVID-19 Cytokine-release Syndrome: Retrospective Study of Two Centers https://doi.org/10.5005/jp-journals-10071-23566 In a retrospective case-control analysis of all COVID-19 patients with severe to critical disease in ICU, they were evaluated for CRS, and 22 patients who met the criterion… Continue reading "(03 Nov 2020) Tocilizumab- significantly reduced the need for invasive ventilation and mortality"

(03 Nov 2020) Hydroxychloroquine- did not prevent severe outcomes or improved clinical scores

November 5, 2020

Treating COVID-19 With Hydroxychloroquine (TEACH): A Multicenter, Double-Blind Randomized Controlled Trial in Hospitalized Patients https://doi.org/10.1093/ofid/ofaa446 In a multicenter, double-blind randomized clinical trial (NCT04369742)of HCQ among patients hospitalized with laboratory-confirmed COVID-19, Subjects were randomized in a 1:1 ratio to HCQ or… Continue reading "(03 Nov 2020) Hydroxychloroquine- did not prevent severe outcomes or improved clinical scores"

(01 Nov 2020) Favipiravir, Lopinavir/R- FPV found to be more beneficial in ICU patients compared to LPV/r

November 5, 2020

Observational study of the effects of Favipiravir vs Lopinavir/Ritonavir on clinical outcomes in critically Ill patients with COVID-19 https://doi.org/10.1111/jcpt.13305 The aim of this study was to describe the clinical experience with FPV and LPV/r in critically ill patients with COVID-19… Continue reading "(01 Nov 2020) Favipiravir, Lopinavir/R- FPV found to be more beneficial in ICU patients compared to LPV/r"

(01 Nov 2020) Hydroxychloroquine, Lopinavir/R- no benefit in improving viral clearance

November 5, 2020

Comparison of antiviral effect for mild-to-moderate COVID-19 cases between lopinavir/ritonavir versus hydroxychloroquine: A nationwide propensity score-matched cohort study https://doi.org/10.1016/j.ijid.2020.10.062 In a nationwide retrospective study, 4,197 patients with mild-to-moderate COVID-19 were included. Patients were categorized into three groups: LPV/r (n =… Continue reading "(01 Nov 2020) Hydroxychloroquine, Lopinavir/R- no benefit in improving viral clearance"

(29 Oct 2020) Anakinra- associated with decrease of the risk for severe respiratory failure

October 31, 2020

Anakinra To Prevent Respiratory Failure In COVID-19 https://www.medrxiv.org/content/10.1101/2020.10.28.20217455v1 In this open-label prospective trial (NCT04357366), 130 patients admitted with SARS-CoV-2 pneumonia SARS-CoV-2 and suPAR levels ≥6 μg/l were assigned to subcutaneous anakinra 100mg once daily for 10 days. The primary outcome… Continue reading "(29 Oct 2020) Anakinra- associated with decrease of the risk for severe respiratory failure"

(29 Oct 2020) Hydroxychloroquine- no benefit in viral load reduction

October 31, 2020

No benefit of hydroxychloroquine on SARS-CoV-2 viral load reduction in non-critical hospitalized patients with COVID-19 https://doi.org/10.1007/s42770-020-00395-x This prospective study comprised consecutive viral load measurements in patients with COVID-19 hospitalized with a moderate illness. Patients received 400 mg of HCQ every… Continue reading "(29 Oct 2020) Hydroxychloroquine- no benefit in viral load reduction"

(28 Oct 2020) Tocilizumab- early administration associated with decreased mortality in critically ill patients

October 31, 2020

Early Tocilizumab Dosing is Associated with Improved Survival In Critically Ill Patients Infected With Sars-CoV-2 https://www.medrxiv.org/content/10.1101/2020.10.27.20211433v1.full.pdf This was a multi-center study of patients infected with SARS-CoV-2, admitted between 3/13/20 and 4/16/20, requiring mechanical ventilation. Parameters that were evaluated included age,… Continue reading "(28 Oct 2020) Tocilizumab- early administration associated with decreased mortality in critically ill patients"